Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIT-HGG-2008 phase II temozolomide trial in pediatric high-grade glioma
2007-000128-42Phase 2Completed
- Sponsor
- Martin-Luther-University Halle-Wittenberg
- Start
- Jun 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in glioma, diffuse intrinsic pontine glioma (DIPG), gliomatosis cerebri (GC) and 1 more, sponsored by Martin-Luther-University Halle-Wittenberg. Primary endpoints: Event status at 6 months after diagnosis and 6-month event-free survival compared with historical control. Started Jun 2008; status: completed.
02
Drugs
temozolomide
03
Conditions
gliomadiffuse intrinsic pontine glioma (DIPG)gliomatosis cerebri (GC)anaplastic astrocytoma (AA)
Beyond the preview
Go deeper on 2007-000128-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000128-42.